AstraZeneca Pharma Ind Share Price

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).As of 14 Jun 2026, AstraZeneca Pharma Ind share price is ₹8,232.50. The stock opened at ₹8,299.00, compared to its previous close of ₹8,228.50. During today's trading session, AstraZeneca Pharma Ind share price moved in the range of ₹8,213.00 to ₹8,299.00, with an average price of ₹8,256.00 for the day. Looking at its last 52-week, the stock has touched a low of ₹8,213.00 and a high of ₹8,299.00. On the performance front, AstraZeneca Pharma Ind share price has declined by 9.89% over the last six months and is down 19.08% on a year-on-year basis.

The market capitalization of AstraZeneca Pharma Ind is ₹20,610 Crs, with a P/E ratio of 109.9 and a dividend yield of 0.44%.